Global Major Depressive Disorder (MDD) Market Insights, Epidemiology and Market Forecasts, 2016-2027
DUBLIN, Jan. 24, 2019 /PRNewswire/ --
The "Major Depressive Disorder (MDD) - Market Insights, Epidemiology and Market Forecast-2027" drug pipelines has been added to ResearchAndMarkets.com's offering.
Major Depressive Disorder (MDD) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical &forecasted epidemiology as well as the market trends of Major Depressive Disorder (MDD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Major Depressive Disorder (MDD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Major Depressive Disorder (MDD) - Disease Understanding and Treatment Algorithm
Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Also called Major Depressive Disorder or clinical depression, it affects how patient feel, think and behave and can lead to a variety of emotional and physical problems.
The exact cause of Major Depressive Disorder (MDD) isn't known. However, there are several factors that can increase the risk of developing the condition. A combination of genes and stress can affect brain chemistry and reduce the ability to maintain mood stability. Changes in the balance of hormones might also contribute to the development of Major Depressive Disorder (MDD).
Symptoms of Major Depressive Disorder (MDD) may include-Feelings of sadness, tearfulness, hopelessness, Sleep disturbances, including insomnia or sleeping too much, Anxiety, agitation or restlessness etc.
The Major Depressive Disorder (MDD) market report gives the thorough understanding of the Major Depressive Disorder (MDD) by including details such as disease definition, clinical manifestations, risk factors, pathogenesis, and diagnostic trends, prognosis and prevention. It also provides treatment algorithms and treatment guidelines for Major Depressive Disorder (MDD) in the US, Europe, and Japan.
Major Depressive Disorder (MDD) Epidemiology
The Major Depressive Disorder (MDD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Total Prevalent population of Major Depressive Disorder (MDD), Gender specific Prevalent of Major Depressive Disorder (MDD), Diagnosed and treatable Cases of Major Depressive Disorder (MDD)] scenario of Major Depressive Disorder (MDD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.
As per Anxiety and Depression Association of America (ADAA), the leading cause of MDD disability in the U.S. for ages 15 to 44.3.MDD affects about 6.7%of the U.S. population age 18 and older in a given year. While Major Depressive Disorder can develop at any age, the median age at onset is 32.5 years old. More prevalent in women than in men.
This research estimates that the prevalent population of Major Depressive Disorder (MDD) will significantly change during the study period [2016-2027].
Major Depressive Disorder (MDD) Drug Chapters
Additionally, there are some FDA approved therapies for the treatment of Major Depressive Disorder (MDD) which include-Aripiprazole (BristolMyers Squibb), Aplenzin (Valeant Pharmaceuticals), Emsam (Somerset pharmaceuticals).
Key players such as Fabre-Kramer Pharmaceuticals, Sage Therapeutics and many others are involved in developing therapies for Major Depressive Disorder (MDD). Expected launch of emerging therapies such as Travivo (Fabre-Kramer Pharmaceuticals), SAGE-217 (Sage Therapeutics) and some other are expected to change the treatment landscape of Major Depressive Disorder (MDD) in upcoming years.
Major Depressive Disorder (MDD) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Key Topics Covered:
1. Report Introduction
2. Major Depressive Disorder (MDD) Market Overview at a Glance
2.1. 7 Major Market Size of Major Depressive Disorder (MDD) in 2017
2.2. 7 Major Market Size of Major Depressive Disorder (MDD) in 2027
3. Disease Background and Overview: Major Depressive Disorder (MDD)
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. 7MM Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
4.2. 7MM Gender specific Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
4.3. 7MM Diagnosed and treatable cases of Major Depressive Disorder (MDD) (2016-2027)
5. Major Depressive Disorder (MDD): Country- Wise Epidemiology
5.1. United States
5.2. Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
5.3. Gender specific Prevalent Cases of Major Depressive Disorder (MDD) (2016-2027)
5.4. Diagnosed and treatable cases of Major Depressive Disorder (MDD) (2016-2027)
5.5. EU-5
5.6. Japan
6. Treatments & Medical Practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Marketed drug
7.1. Aripiprazole: BristolMyers Squibb
7.2. Aplenzin: Valeant Pharmaceuticals
8. Emerging Therapies
8.1. Key Cross Competition
8.2. Travivo: Fabre-Kramer Pharmaceuticals
8.3. SAGE-217: Sage Therapeutics
9. Major Depressive Disorder (MDD) Market Size
9.1. Key Findings
9.2. Total 7MM Major Depressive Disorder (MDD) Market Analysis
10. 7MM: Country-Wise Market Analysis
10.1. United States Market Size
10.2. Germany Market Size
10.3. France Market Size
10.4. United Kingdom Market Size
10.5. Spain Market Size
10.6. Italy Market Size
10.7. Japan Market Size
11. Market Drivers
12. Market Barriers
Companies Mentioned
- Fabre-Kramer Pharmaceuticals
- Sage Therapeutics
- BristolMyers Squibb
- Valeant Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/r98mrs/global_major?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article